The medical device news magazine is the latest source for industry scoop. In this article, we take a look at which executives are on the move.
As the medical device industry rapidly expands, so does the need for executive leadership. Recently, several top executives have made moves within the industry. Some have taken new positions at other companies, while others have started their own businesses. Here’s a look at who’s been making headlines lately.
Dr Hanjing Xie Appointed New CMO of Neogap
Dr Hanjing Xie will oversee Neogap's clinical development programs and pipeline and provide medical oversight for the company's first-in-human study.
Inogen Announces Appointment of Tom West to Board of Directors and Retirement of Board Member Kristen Miranda
Tom West brings additional general management and operational experience to the Inogen Board with his history of leadership and business success in medical technology and life sciences healthcare spaces,” said Elizabeth Mora, Chairperson of the Board.
Avania Names MedTech Industry Veteran, Todd M Pope, New Chairman of the Board
Todd M Pope brings 30 years of technology, medical device, and leadership experience across large cap and startup MedTech and was named to TIME Magazine’s 2018 list of 50 Most Influential People in Healthcare.
Soleo Health Chief Executive Officer Drew Walk Named to NHIA Board of Directors
Drew Walk joins a group of seasoned home infusion experts on the NHIA board, an industry governing body. NHIA is the leading industry association providing education, information, advocacy and resources for the nation’s home and alternate site infusion provider community and the manufacturers, suppliers and service companies who support them.
Foster Supply Chain Solutions Hires Brian Savel for Midwest Business Development Representative
Brian Savel brings an excellent and diverse track record of successful sales/business development experience to Foster SCS and his customers and potential customers.
ViroCell Appoints John A Dawson CBE as Chairman of the Board of Directors
John A Dawson said, “I am delighted to join ViroCell’s Board of Directors as its Chairman to help it become a global leader in the cell and gene therapy clinical trials CDMO market. I am impressed by both the quality and experience of ViroCell’s team and the speed with which they have scaled the organisation. Now, with access to state-of-the-art facilities, ViroCell stands ready to begin manufacturing and delivering vectors to clients. What makes ViroCell unique and stand out among other CDMOs is that its team’s track record of designing and manufacturing vectors for clinical trials over twenty years places them among the most knowledgeable and experienced vector teams in the world. The number of partners that have approached ViroCell for their vector needs is a significant leading indicator of future success. I am excited to join the company.”